Скачать или смотреть Schizophrenia Care: Addressing Symptoms With Dr. Christoph Correll

Complete the activity and claim credit here: https://bit.ly/3IEsBu9

View and download the slide deck here: https://www.slideshare.net/slideshow/...

0:00 – Introduction
1:20 – Burden of schizophrenia
5:42 – Pharmacologic basis of antipsychotics
7:18 – Pathophysiology of schizophrenia
10:10 – Lumateperone
14:35 - Olanzapine/samidorphan
18:05 – Muscarinic angonism
27:05 – Xanomeline + trospium chloride
30:31 – ARISE
31:51 – Emerging therapy
32:41 – Muscarinic modulators in development
33:38 - LB-102, methylated amisulpride
35:07 – Evanamide
36:23 – Long-acting injectable antipsychotics
37:20 – Paliperidone 6-monthly intramuscular injection
37:58 – Risperidone subcutaneous injection
38:45 - Olanzapine subcutaneous injection
41:06 – Negative symptoms
42:52 – Antipsychotics
43:31 – Co-treatment for negative symptoms
44:13 - KAR-XT for prominent negative symptoms
44:46 – Cognitive dysfunction in schizophrenia
48:32 – Effect of antipsychotics on cognition
49:09 – The glutamate receptor system and cognition
50:02 – Pharmacotherapies
50:28 - KAR-XT and cognitive function
51:08 – Collaborative care planning
52:27 – Motivational decision making
52:56 - Tailoring treatment
55:04 – Case: Mr. TG
58:03 – Key takeaways

Follow us here:
Facebook   / i3health  
Instagram   / i3health  
Linkedin   / i3health  
Soundcloud   / i3-health  
X   / i3health  

STATEMENT OF NEED
Schizophrenia is a complex psychiatric disorder that affects approximately 24 million people worldwide. The disease is characterized by heterogenous symptom trajectories which drastically impact patients’ quality of life and outcomes (Kinon et al, 2024). Schizophrenia includes three primary symptom domains: positive symptoms, such as hallucinations, delusions, illogical thought and behavior changes, hyperactivity, and thought disorders; negative symptoms, such as apathy, lethargy, and social withdrawal; and cognitive symptoms, such as difficulty in abstract thinking, poor attention, disorientation, stereotyped thinking, and conceptual disorganization (Agius et al, 2024; Kinon et al, 2024; McCutcheon et al, 2023). Currently, the approved treatments for schizophrenia are limited in their efficacy across symptom domains (Kinon et al, 2024). Therefore, it is crucial for the care team to remain up to date not only on advances in new and emerging therapeutic agents, but also on patient-centered approaches that incorporate shared decision making in order to optimize outcomes for their patients. This activity, chaired by Dr. Christoph U. Correll, Professor of Psychiatry and Molecular Medicine at Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, and Professor and Chair of the Department of Child and Adolescent Psychiatry at Charité – University Medicine in Berlin, Germany, will explore approaches for addressing positive, negative, and cognitive symptoms of schizophrenia, underscoring new and emerging strategies for success.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
Relevant financial relationships exist between the following individuals and ineligible companies:

Christoph U. Correll, MD, discloses that he has served on an advisory board or panel for AbbVie, Allergan, Angelini, Boehringer Ingelheim, Bristol Myers Squibb, Cerevel, Compass, Gedeon Richter, Janssen/J&J, Karuna, LB Pharma, Life Science, Lundbeck, MedInCell, Merck, Neuraxpharm, Neurelis, Neurocrine, Newron, Novo Nordisk, Otsuka, Recordati, Rovi, Sage, Seqirus, Sunovion, Supernus, Teva, Vertex, and Viatris; that he has served as a consultant for AbbVie, Alkermes, Allergan, Angelini, Aristo, Autobahn, Boehringer-Ingelheim, Bristol Myers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Draig, Eli Lilly, Eumentis Therapeutics, Gedeon Richter, GH, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neuraxpharm, Neurocrine, Neurelis, NeuShen, Newron, Noven, Novo Nordisk, Orion Pharma, Otsuka, PPD Biotech, Recordati, Relmada, Response Pharmaceutical, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Terran, Teva, Tolmar, Vertex, Viatris, and Xenon; that he has received grants/research support from Boehringer-Ingelheim, Janssen, and Takeda; and that he is a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quanticel, and Terran.

This activity has been supported through an independent educational grant from Teva Pharmaceuticals and Bristol Myers Squibb.

#SchizophreniaCare #MentalHealth #PsychiatryEducation #PatientOutcomes